Ropes & Gray represented Foghorn Therapeutics in its registered direct offering of 12,743,039 shares of common stock $5.51 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock for total gross proceeds of approximately $110 million. The closing was announced in a May 22 press release.
Foghorn is a Cambridge, Mass., biopharmaceutical company developing a novel class of oncology medicines that target genetically-determined dependencies within the chromatin regulatory system.
The Ropes & Gray team included capital markets partner Rachel Phillips, life sciences partner Marc Rubenstein, tax partner Eric Behl-Remijan, and life sciences regulatory & compliance partner Kellie Combs.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.